Johnson & Johnson gets FDA approval for Ottava robot
Featured

Johnson & Johnson gets FDA approval for Ottava robot

Gene Therapy

User Blocked After Violation of Platform Policies
Gene Therapy
July 20, 2026

User Blocked After Violation of Platform Policies

Bispecific antibodies are emerging immunotherapy for relapsed lymphoma and leukemia, offering a viable option when...

Website blocks users with error message
Gene Therapy
July 18, 2026

Website blocks users with error message

Heart failure management is shifting as pharmacists take on a larger role. Discover how they...

User blocked from platform after violation
Gene Therapy
July 14, 2026

User blocked from platform after violation

Medicare introduces a $50 monthly copay for GLP-1 weight-loss drugs, offering affordable access to eligible...

NF Research

Read our latest NF Research articles.

User Receives Unexpected Block Notification
NF Research July 12, 2026

User Receives Unexpected Block Notification

Explore the 2026 pulmonary embolism guidelines released by the American Heart Association and ACC, detailing...

Pharmacists Offer Practical Tips to Prevent Drink Spiking
NF Research July 2, 2026

Pharmacists Offer Practical Tips to Prevent Drink Spiking

Learn practical drink spiking prevention tips from pharmacists, including how OTC test strips work and...

Patient Briefs

Trial Moves

All Posts

Johnson & Johnson gets FDA approval for Ottava robot
Trial Moves

Johnson & Johnson gets FDA approval for Ottava robot

Johnson & Johnson gets FDA approval for Ottava robot to compete with da Vinci in soft tissue surgery systems.

Philips secures FDA approval for pulse oximeter
Patient Briefs

Philips secures FDA approval for pulse oximeter

Philips secures FDA approval for a new pulse oximeter addressing racial bias with improved accuracy across skin tones.

Tempus Agrees to Buy Personalis for 1 Billion
Tumor Watch

Tempus Agrees to Buy Personalis for 1 Billion

Tempus AI agrees to buy Personalis for $1.5 billion to enhance cancer diagnostics and treatment selection with molecular residual disease...

Edwards Sees Boost in Heart Valve Sales
NF Research

Edwards Sees Boost in Heart Valve Sales

Edwards sees boost in heart valve sales driven by increasing demand for TAVR devices and newer treatments.

Dexcom joins FDA digital health pilot program
Patient Briefs

Dexcom joins FDA digital health pilot program

Dexcom joins the FDA’s digital health pilot program to accelerate innovative medical technologies with real-world data and faster approvals.

Website Blocks User Access with Error Message
Tumor Watch

Website Blocks User Access with Error Message

US adult obesity rates climbed to 41% between 1999 and 2023. New data reveals severe obesity doubling and abdominal obesity...

User Blocked After Repeated Policy Violations
Tumor Watch

User Blocked After Repeated Policy Violations

Explore the latest breast cancer treatment developments and the challenges of sequencing antibody-drug conjugates to optimize patient outcomes in oncology.

User Blocked After Violation of Platform Policies
Gene Therapy

User Blocked After Violation of Platform Policies

Bispecific antibodies are emerging immunotherapy for relapsed lymphoma and leukemia, offering a viable option when CAR T‑cell treatment isn’t possible,...

User Claims Account Blocked Without Explanation
Patient Briefs

User Claims Account Blocked Without Explanation

Bispecific therapy program by American Oncology Network offers safe outpatient dosing guidelines for community clinics, ensuring close monitoring and patient...

Website blocks users with error message
Gene Therapy

Website blocks users with error message

Heart failure management is shifting as pharmacists take on a larger role. Discover how they are improving outcomes for patients...

Show More →